Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds BTIG Downgrades OncoSec Medical to Neutral

BTIG Downgrades OncoSec Medical to Neutral

BTIG analyst Kaveri Pohlman downgrades OncoSec Medical (NASDAQ:ONCS) from Buy to Neutral.

byBenzinga Newsdesk

November 14, 2022

1 minute read

BTIG analyst Kaveri Pohlman downgrades OncoSec Medical (NASDAQ:ONCS) from Buy to Neutral.

Analyst Ratings

A Glimpse Into The Expert Outlook On Illinois Tool Works Through 7 Analysts

By Benzinga Insights

May 1, 10:00 AM

Analysts’ ratings for Illinois Tool Works (NYSE:ITW) over the last quarter vary from bullish to bearish, as provided…

ITW

Morgan Stanley Maintains Overweight on Alphatec Holdings, Raises Price Target to $18

By Benzinga Newsdesk

March 1, 8:57 AM

Morgan Stanley analyst Drew Ranieri maintains Alphatec Holdings (NASDAQ:ATEC) with a Overweight and raises the price target from $17 to $18.

ATEC

July Game Sales Surge In Europe: 11.6M Units Sold, 10-Year-Old Grand Theft Auto 5 Dominates Charts

By Franca Quarneti

August 22, 4:57 PM

Europe saw a substantial increase in console and PC game sales in July, reaching 11.6 million units, which was up by 34% from the same period in 2022.

ATVI

Analyst Ratings

Analyst Expectations for Ascendis Pharma’s Future

By Benzinga Insights

July 24, 3:00 PM

Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND) within the last quarter: Bullish Somewhat Bullish Indifferent…

ASND

BTIG Downgrades OncoSec Medical to Neutral

Related Posts

A Glimpse Into The Expert Outlook On Illinois Tool Works Through 7 Analysts

Morgan Stanley Maintains Overweight on Alphatec Holdings, Raises Price Target to $18

July Game Sales Surge In Europe: 11.6M Units Sold, 10-Year-Old Grand Theft Auto 5 Dominates Charts

Analyst Expectations for Ascendis Pharma’s Future